Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration

Br J Pharmacol. 2011 Mar;162(6):1225-38. doi: 10.1111/j.1476-5381.2010.01118.x.

Abstract

Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid thought to be dysregulated in a variety of disease conditions. In this review, we discuss the roles of S1P in cancer and in wet age-related macular degeneration. We also explore potential treatment strategies for these disorders, including the utility of anti-S1P antibodies acting as molecular sponges to neutralize dysregulated S1P in relevant tissues.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Drug Discovery
  • Humans
  • Lysophospholipids / immunology*
  • Lysophospholipids / metabolism*
  • Molecular Targeted Therapy
  • Neoplasms / metabolism
  • Neoplasms / therapy*
  • Receptors, Lysosphingolipid / metabolism*
  • Signal Transduction / drug effects
  • Sphingosine / analogs & derivatives*
  • Sphingosine / immunology
  • Sphingosine / metabolism
  • Wet Macular Degeneration / therapy*

Substances

  • Antibodies, Monoclonal
  • Lysophospholipids
  • Receptors, Lysosphingolipid
  • sphingosine 1-phosphate
  • Sphingosine